FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
|Videos|September 20, 2016
CBTF Programs and Research
Author(s)Children's Brain Tumor Foundation
Children's Brain Tumor Foundation explains the importance of their research and programs.
Advertisement
Why is it so important to support CBTF's research and programs? Watch this video featuring families, survivors, and some of our greatest supporters to find out why.
Advertisement
Related to this article
ANA President Jennifer Mensik Kennedy outlines systemic nurse fatigue mitigation policies, emphasizing patient safety and acuity across oncology care.
From ICN 2026, Heather Jackson and Ashley Johnson detail APP breast care access models, global cancer pain barriers, and burnout mitigation tactics.
FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
Yesne Alici, MD, of Memorial Sloan Kettering Cancer Center discusses key delirium screening, patient capacity, and bioethics in oncology nursing care.
A nurse-led support program significantly reduces death anxiety in women with breast cancer on hormonal therapy, study finds.
FDA approves lutetium lu 177 dotatate (Bravnetsa) as bioequivalent to Lutathera for GEP-NETs. Review key nursing takeaways and safety guidelines.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Clear Cell RCC
2
FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma
3
ICN 2026: APP Leadership, Cancer Pain Care, and Nurse-Led Rapid Care Models
4
How On-Body Treatment Delivery Reduces Nursing Burden in Myeloma Care
5